|Bid||16.51 x 1200|
|Ask||16.54 x 900|
|Day's range||16.32 - 17.03|
|52-week range||16.00 - 236.50|
|Beta (5Y monthly)||1.89|
|PE ratio (TTM)||N/A|
|Earnings date||27 Feb 2023 - 03 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||78.17|
Novavax (NASDAQ: NVAX) investors are looking at a share price decline of more than 90% over the past 12 months, and the shares are now trading close to their 52-week low. Importantly, Gavi has paid Novavax $700 million in the last two years, and its $350 million payment in 2021 accounted for a large fraction of the biotech's $1.1 billion in total revenue for the year.
It's been a difficult year for stocks (and investors) in general. But certain stocks have had a particularly trying time. These companies faced specific challenges -- and that's sent their shares tumbling further than the general market.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.